A phase 1 study of the IAP inhibitor xevinapant (Debio 1143) to evaluate food effect and drug-drug interactions with a proton pump inhibitor in healthy volunteers

Presented at AACR Annual Meeting 2024

V. Nicolas-Métral,¹ E. Rouits,^1* C. Riff,^1* D. Spaggiari,¹ N. Wiedemann,¹ P. Colin,^1* E. Harrison-Moench,² R. Crabbé,¹ H. Nauwelaerts,¹ A. Schroeder,² C. Haefliger,¹ Y. Vugmeyster³

1 Debiopharm, Lausanne, Switzerland
2 The healthcare business of Merck KGaA, Darmstadt, Germany;
3 EMD Serono, Billerica, MA, USA
*Affiliation at the time the study was conducted

We report results of this randomized, 2-stage, phase 1 study evaluating food effect, drug-drug interactions with a proton pump inhibitor (pantoprazole) and the relative bioavailability of 2 formulations of xevinapant.